Latest News & Features
article
As a follow-on from last week's Regeneron v Kymab webinar, where we looked at how and why the Supreme Court reversed the Court of Appeal and found Regeneron's patents for transgenic mouse technology invalid for insufficiency, we pick up the discussion to reflect on the broader impact of the ruling. 11 March 2021
Europe
The UK has been urged to back a proposed IP waiver related to COVID-19 treatments before the World Trade Organisation by business leaders, academics, economists and trade unions. 11 March 2021
Americas
AstraZeneca has won a three-year legal battle against UK generics manufacturer Mylan Pharmaceuticals over its asthma inhaler patents. 9 March 2021
Biotechnology
The fallout from the landmark Regeneron v Kymab is still being weighed by the UK life sciences community. 9 March 2021
Big Pharma
The director general of the World Health Organization has called for a waiver on IP rights to ensure more equitable access to COVID-19 vaccines. 9 March 2021
Big Pharma
On June 24, 2020, a seven-year long legal battle between two biotech companies finally concluded in the UK. 8 March 2021
Big Pharma
UK innovation hub CPI has received a further £5 million investment from the UK government to support the development of new mRNA vaccines to protect against new variants of COVID-19. 4 March 2021
Big Pharma
GlaxoSmithKline has avoided paying $57 million in damages after a US supreme court reversed a ruling that the pharmaceutical company should not have stopped issuing royalties on a lupus drug. 4 March 2021
article
Join LSPN Connect for an in-depth two-part look at the Regeneron v Kymab case. On Thursday, March 4, we will be joined by some of the participants of the latest proceedings before the UK Supreme Court. 4 March 2021
Medtech
Thom Tillis, ranking member of the senate IP subcommittee, has urged US president Joe Biden to oppose ‘harmful’ proposals to waive rights related to COVID-19 vaccines currently in discussions at the World Trade Organisation. 2 March 2021